7/10/23, 11:57 AM Ontology Browser

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Stage\_3B\_NSCLC

## Annotations (1)

• rdfs:comment "Stage IIIB NSCLC has spread to lymph nodes that are near the other lung or in the neck, and may also have grown into important structures in the chest. These cancers can't be removed completely by surgery. As with other stages of lung cancer, treatment depends on the patient's overall health. If you are in fairly good health you may be helped by chemotherapy (chemo) combined with radiation therapy (known as chemoradiation). Some people can even be cured with this treatment. If the cancer stays under control after 2 or more treatments of chemoradiation, the immunotherapy drug durvalumab (Imfinzi) can be given for up to a year to help keep the cancer stable. Patients who are not healthy enough for this combination are often treated with radiation therapy alone, or, less often, chemo alone. If surgery, radiation, and chemoradiation aren't likely to be good treatment options, an immunotherapy drug such as pembrolizumab (Keytruda) or cemiplimab (Libtayo) may be considered as the first treatment. These cancers can be hard to treat, so taking part in a clinical trial of newer treatments may be a good option for some people."

## Superclasses (1)

Non-Small\_Cell\_LC

## Disjoints (690)

```
'\'Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_\'', '\'Afinitor_(Everolimus)\'',
'\'Afinitor_Disperz_(Everolimus)_\'', '\'Alecensa_(Alectinib)_\'', '\'Alimta_(Pemetrexed_Disodium)_\'',
'\'Alunbrig_(Brigatinib)_\'', '\'Alymsys_(Bevacizumab)_\'', '\'Avastin_(Bevacizumab)_\'',
'\'Cyramza_(Ramucirumab)_\", '\'Enhertu_(Fam-Trastuzumab_Deruxtecan-nxki)_\",
\\'\'Etopophos_(Etoposide_Phosphate)_\'', \\'Exkivity_(Mobocertinib_Succinate)_\\'', \\'Gavreto_(Pralsetinib)_\\'', \\'Gemzar_(Gemcitabine_Hydrochloride)_\\'', \\'Gilotrif_(Afatinib_Dimaleate)_\\'', \\'Hycamtin_(Topotecan_Hydrochloride)_\\'', \\'Imfinzi_(Durvalumab)_\\'', \\'Imjudo_(Tremelimumab-actl)_\\'', \\'Infugem_(Gemcitabine_Hydrochloride)_\\'', \\'Iressa_(Gefitinib)_\\'', \\'Keytruda_(Pembrolizumab)_\\'',
'\'Krazati_(Adagrasib)_\'', '\'Libtayo_(Cemiplimab-rwlc)_\'', '\'Lorbrena_(Lorlatinib)_\'',
'\'Lumakras_(Sotorasib)_\'', '\'Mekinist_(Trametinib_Dimethyl_Sulfoxide)_\'', '\'Mvasi_(Bevacizumab)_\'',
'\'Opdivo_(Nivolumab)_\", '\'Portrazza_(Necitumumab)_\", '\'Retevmo_(Selpercatinib)_\",
'\'Rozlytrek_(Entrectinib)_\'', '\'Rybrevant_(Amivantamab-vmjw)_\'',
'\'Tabrecta_(Capmatinib_Hydrochloride)_\'', '\'Tafinlar_(Dabrafenib_Mesylate)_\'',
'\'Tagrisso_(Osimertinib_Mesylate)_\'', '\'Taxotere_(Docetaxel)_\'', '\'Tecentriq_(Atezolizumab)_\'',
'\'Tepmetko_(Tepotinib_Hydrochloride)_\'', '\'Trexall_(Methotrexate_Sodium)_\'', '\'Vizimpro_(Dacomitinib)_\'',
'\'Xalkori_(Crizotinib)_\'', '\'Yervoy_(Ipilimumab)_\'', '\'Zirabev_(Bevacizumab)_\'', '\'Zykadia_(Ceritinib)_\'',
4A NSCLC, 4B NSCLC, Adagrasib, Adherence Based on Socioeconomics LC, Adherence Factors LC,
Adverse_Reactions_ABRAX, Adverse_Reactions_ADAGR, Adverse_Reactions_AFATI, Adverse_Reactions_AFINI,
Adverse_Reactions_AFINIT, Adverse_Reactions_ALECE, Adverse_Reactions_ALIMT, Adverse_Reactions_ALUNB,
Adverse_Reactions_ALYMS, Adverse_Reactions_AMIVA, Adverse_Reactions_ATEZO, Adverse_Reactions_AVAST,
Adverse Reactions BRIGA, Adverse Reactions CAPMA, Adverse Reactions CEMIP, Adverse Reactions CYRAM,
Adverse_Reactions_DOXOR, Adverse_Reactions_DURVA, Adverse_Reactions_ENHER,
Adverse_Reactions_ENTRE, Adverse_Reactions_ERLOT, Adverse_Reactions_ETOP, Adverse_Reactions_ETOPO,
Adverse_Reactions_EXKIV, Adverse_Reactions_GAVRE, Adverse_Reactions_GEFIT, Adverse_Reactions_GEMZA,
Adverse Reactions GILOT, Adverse Reactions HYCAM, Adverse Reactions IMFIN, Adverse Reactions IMJUD,
Adverse_Reactions_INFUG, Adverse_Reactions_IRESS, Adverse_Reactions_KEYTR, Adverse_Reactions_KRAZA,
Adverse_Reactions_LIBTA, Adverse_Reactions_LORBR, Adverse_Reactions_LUMAK, Adverse_Reactions_LURB,
Adverse_Reactions_MEKIN, Adverse_Reactions_METH, Adverse_Reactions_MVASI, Adverse_Reactions_OPDIV,
Adverse_Reactions_PORTR, Adverse_Reactions_RAMUC, Adverse_Reactions_RETEV, Adverse_Reactions_ROZLY,
Adverse_Reactions_RYBRE, Adverse_Reactions_SELPE, Adverse_Reactions_SOTOR, Adverse_Reactions_TABRE,
Adverse_Reactions_TAFIN, Adverse_Reactions_TAGRIS, Adverse_Reactions_TAXOT, Adverse_Reactions_TECEN,
Adverse_Reactions_TEPME, Adverse_Reactions_TOPO, Adverse_Reactions_TRAME, Adverse_Reactions_TREME,
Adverse Reactions TREXA, Adverse Reactions VINOR, Adverse Reactions VIZIM, Adverse Reactions XALKO,
Adverse_Reactions_YERVO, Adverse_Reactions_ZIRAB, Adverse_Reactions_ZYKAD, Afatinib_Dimaleate_, Age,
Air_Pollution, Amivantamab-vmjw_, Atezolizumab_, Behavioral_Factors_LC, Beta_Carotene_Supplements_LC,
Bio Sensors LC, Biological Effects LC, Breathalyzer LC, Breathing LC, Brigatinib ,
Capmatinib_Hydrochloride_, Causes_and_Risks_LC, Cemiplimab-rwlc_, Chemical_Sensors_LC,
Choosing_Quality_of_Life_-_Reasons_People_Forego_Treatment, Choosing_Survival_-
```

Deciding\_to\_Undergo\_Treatment, Complications\_LC, Contraindications\_ABRAX, Contraindications\_ADAGR, Contraindications AFATI, Contraindications AFINI, Contraindications AFINIT, Contraindications ALECE, Contraindications\_ALIMT, Contraindications\_ALUNB, Contraindications\_ALYMS, Contraindications\_AMIVA, Contraindications ATEZO, Contraindications AVAST, Contraindications BRIGA, Contraindications CAPMA, Contraindications CEMIP, Contraindications CYRAM, Contraindications DOXOR, Contraindications DURVA, Contraindications ENHER, Contraindications ENTRE, Contraindications ERLOT, Contraindications ETOP, Contraindications\_ETOPO, Contraindications\_EXKIV, Contraindications\_GAVRE, Contraindications\_GEFIT, Contraindications\_GEMZA, Contraindications\_GILOT, Contraindications\_HYCAM, Contraindications\_IMFIN, Contraindications IMJUD, Contraindications INFUG, Contraindications IRESS, Contraindications KEYTR, Contraindications KRAZA, Contraindications LIBTA, Contraindications LORBR, Contraindications LUMAK, Contraindications\_LURB, Contraindications\_MEKIN, Contraindications\_METH, Contraindications\_MVASI, Contraindications\_OPDIV, Contraindications\_PORTR, Contraindications\_RAMUC, Contraindications\_RETEV, Contraindications\_ROZLY, Contraindications\_RYBRE, Contraindications\_SELPE, Contraindications\_SOTOR, Contraindications\_TABRE, Contraindications\_TAFIN, Contraindications\_TAGRIS, Contraindications\_TAXOT, Contraindications\_TECEN, Contraindications\_TEPME, Contraindications\_TOPO, Contraindications\_TRAME, Contraindications\_TREME, Contraindications\_TREXA, Contraindications\_VINOR, Contraindications\_VIZIM, Contraindications XALKO, Contraindications YERVO, Contraindications ZIRAB, Contraindications ZYKAD, Cultural\_Beliefs\_and\_Perceptions, Cultural\_LC, Degrees\_of\_Smoking\_LC, Demographic\_Factors\_LC, Diet\_LC, Disparities\_in\_Incidence, Dosage\_and\_Administration\_ABRAX, Dosage\_and\_Administration\_ADAGR, Dosage\_and\_Administration\_AFATI, Dosage\_and\_Administration\_AFINI, Dosage\_and\_Administration\_AFINIT, Dosage\_and\_Administration\_ALECE, Dosage\_and\_Administration\_ALIMT, Dosage\_and\_Administration\_ALUNB, Dosage\_and\_Administration\_ALYMS, Dosage\_and\_Administration\_AMIVA, Dosage\_and\_Administration\_ATEZO, Dosage\_and\_Administration\_AVAST, Dosage\_and\_Administration\_BRIGA, Dosage\_and\_Administration\_CAPMA, Dosage\_and\_Administration\_CEMIP, Dosage\_and\_Administration\_CYRAM, Dosage\_and\_Administration\_DOXOR, Dosage and Administration DURVA, Dosage and Administration ENHER, Dosage and Administration ENTRE, Dosage\_and\_Administration\_ERLOT, Dosage\_and\_Administration\_ETOP, Dosage\_and\_Administration\_ETOPO, Dosage\_and\_Administration\_EXKIV, Dosage\_and\_Administration\_GAVRE, Dosage\_and\_Administration\_GEFIT, Dosage and Administration GEMZA, Dosage and Administration GILOT, Dosage and Administration HYCAM, Dosage\_and\_Administration\_IMFIN, Dosage\_and\_Administration\_IMJUD, Dosage\_and\_Administration\_INFUG, Dosage\_and\_Administration\_IRESS, Dosage\_and\_Administration\_KEYTR, Dosage\_and\_Administration\_KRAZA, Dosage\_and\_Administration\_LIBTA, Dosage\_and\_Administration\_LORBR, Dosage\_and\_Administration\_LUMAK, Dosage and Administration LURB, Dosage and Administration MEKIN, Dosage and Administration METH, Dosage\_and\_Administration\_MVASI, Dosage\_and\_Administration\_OPDIV, Dosage\_and\_Administration\_PORTR, Dosage and Administration RAMUC, Dosage and Administration RETEV, Dosage and Administration ROZLY, Dosage and Administration RYBRE, Dosage and Administration SELPE, Dosage and Administration SOTOR, Dosage\_and\_Administration\_TABRE, Dosage\_and\_Administration\_TAFIN, Dosage\_and\_Administration\_TAGRIS, Dosage\_and\_Administration\_TAXOT, Dosage\_and\_Administration\_TECEN, Dosage\_and\_Administration\_TEPME, Dosage\_and\_Administration\_TOPO, Dosage\_and\_Administration\_TRAME, Dosage\_and\_Administration\_TREME, Dosage and Administration TREXA, Dosage and Administration VINOR, Dosage and Administration VIZIM, Dosage and Administration XALKO, Dosage and Administration YERVO, Dosage and Administration ZIRAB, Dosage\_and\_Administration\_ZYKAD, Dosage\_Forms\_and\_Strengths\_ABRAX, Dosage\_Forms\_and\_Strengths\_ADAGR, Dosage\_Forms\_and\_Strengths\_AFATI, Dosage Forms and Strengths AFINI, Dosage Forms and Strengths AFINIT, Dosage Forms and Strengths ALECE, Dosage Forms and Strengths ALIMT, Dosage Forms and Strengths ALUNB, Dosage Forms and Strengths ALYMS, Dosage Forms and Strengths AMIVA, Dosage Forms and Strengths ATEZO, Dosage Forms and Strengths AVAST, Dosage Forms and Strengths BRIGA, Dosage Forms and Strengths\_CAPMA, Dosage\_Forms\_and\_Strengths\_CEMIP, Dosage Forms and Strengths CYRAM, Dosage Forms and Strengths DOXOR, Dosage Forms and Strengths DURVA, Dosage Forms and Strengths ENHER, Dosage Forms and Strengths ENTRE, Dosage Forms and Strengths ERLOT, Dosage Forms and Strengths ETOP, Dosage Forms and Strengths ETOPO, Dosage\_Forms\_and\_Strengths\_EXKIV, Dosage\_Forms\_and\_Strengths\_GAVRE, Dosage Forms and Strengths GEFIT, Dosage Forms and Strengths GEMZA, Dosage Forms and Strengths GILOT, Dosage Forms and Strengths HYCAM, Dosage\_Forms\_and\_Strengths\_IMFIN, Dosage\_Forms\_and\_Strengths\_IMJUD, Dosage\_Forms\_and\_Strengths\_INFUG, Dosage\_Forms\_and\_Strengths\_IRESS, Dosage Forms and Strengths KEYTR, Dosage Forms and Strengths KRAZA, Dosage\_Forms\_and\_Strengths\_LIBTA, Dosage\_Forms\_and\_Strengths\_LORBR, Dosage\_Forms\_and\_Strengths\_LUMAK, Dosage\_Forms\_and\_Strengths\_LURB, Dosage\_Forms\_and\_Strengths\_MEKIN, Dosage\_Forms\_and\_Strengths\_METH, Dosage Forms and Strengths MVASI, Dosage Forms and Strengths OPDIV, Dosage Forms and Strengths PORTR, Dosage Forms and Strengths RAMUC, Dosage\_Forms\_and\_Strengths\_RETEV, Dosage\_Forms\_and\_Strengths\_ROZLY, Dosage\_Forms\_and\_Strengths\_RYBRE, Dosage\_Forms\_and\_Strengths\_SELPE,

7/10/23, 11:57 AM Ontology Browser

```
Dosage_Forms_and_Strengths_SOTOR, Dosage_Forms_and_Strengths_TABRE,
Dosage_Forms_and_Strengths_TAFIN, Dosage_Forms_and_Strengths_TAGRIS,
Dosage_Forms_and_Strengths_TAXOT, Dosage_Forms_and_Strengths_TECEN,
Dosage_Forms_and_Strengths_TEPME, Dosage_Forms_and_Strengths_TOPO,
Dosage_Forms_and_Strengths_TRAME, Dosage_Forms_and_Strengths_TREME,
Dosage_Forms_and_Strengths_TREXA, Dosage_Forms_and_Strengths_VINOR,
Dosage_Forms_and_Strengths_VIZIM, Dosage_Forms_and_Strengths_XALKO,
Dosage_Forms_and_Strengths_YERVO, Dosage_Forms_and_Strengths_ZIRAB,
Dosage Forms and Strengths ZYKAD, Doxorubicin Hydrochloride, Drug Interactions ABRAX,
Drug_Interactions_ADAGR, Drug_Interactions_AFATI, Drug_Interactions_AFINI, Drug_Interactions_AFINIT,
Drug_Interactions_ALECE, Drug_Interactions_ALIMT, Drug_Interactions_ALUNB, Drug_Interactions_ALYMS,
Drug_Interactions_AMIVA, Drug_Interactions_ATEZO, Drug_Interactions_AVAST, Drug_Interactions_BRIGA,
Drug_Interactions_CAPMA, Drug_Interactions_CEMIP, Drug_Interactions_CYRAM, Drug_Interactions_DOXOR,
Drug_Interactions_DURVA, Drug_Interactions_ENHER, Drug_Interactions_ENTRE, Drug_Interactions_ERLOT,
Drug_Interactions_ETOP, Drug_Interactions_ETOPO, Drug_Interactions_EXKIV, Drug_Interactions_GAVRE,
Drug_Interactions_GEFIT, Drug_Interactions_GEMZA, Drug_Interactions_GILOT, Drug_Interactions_HYCAM,
Drug_Interactions_IMFIN, Drug_Interactions_IMJUD, Drug_Interactions_INFUG, Drug_Interactions_IRESS,
Drug_Interactions_KEYTR, Drug_Interactions_KRAZA, Drug_Interactions_LIBTA, Drug_Interactions_LORBR,
Drug_Interactions_LUMAK, Drug_Interactions_LURB, Drug_Interactions_MEKIN, Drug_Interactions_METH,
Drug_Interactions_MVASI, Drug_Interactions_OPDIV, Drug_Interactions_PORTR, Drug_Interactions_RAMUC,
Drug_Interactions_RETEV, Drug_Interactions_ROZLY, Drug_Interactions_RYBRE, Drug_Interactions_SELPE,
Drug_Interactions_SOTOR, Drug_Interactions_TABRE, Drug_Interactions_TAFIN, Drug_Interactions_TAGRIS,
Drug_Interactions_TAXOT, Drug_Interactions_TECEN, Drug_Interactions_TEPME, Drug_Interactions_TOPO,
Drug_Interactions_TRAME, Drug_Interactions_TREME, Drug_Interactions_TREXA, Drug_Interactions_VINOR,
Drug_Interactions_VIZIM, Drug_Interactions_XALKO, Drug_Interactions_YERVO, Drug_Interactions_ZIRAB,
Drug_Interactions_ZYKAD, Durvalumab_, E-Cigarettes_LC, Electronic_Sensors_LC, Emotions_LC,
End_of_Life_Decisions, Entrectinib_, Environmental_Factors_LC, Enzymatic_Sensors_LC,
Erlotinib_Hydrochloride_, Etoposide_, Exercise_LC, Extensive_Stage_SCLC, Family_History_LC, Gefitinib_,
Genomic_Sequencing_LC, Geographical_Location, Habits_LC, HIV_Infection_LC, Immunosensors_LC,
Increased_Susceptibility_LC, Indications_and_Usage_ABRAX, Indications_and_Usage_ADAGR,
Indications_and_Usage_AFATI, Indications_and_Usage_AFINI, Indications_and_Usage_AFINIT,
Indications and Usage ALECE, Indications and Usage ALIMT, Indications and Usage ALUNB,
Indications_and_Usage_ALYMS, Indications_and_Usage_AMIVA, Indications_and_Usage_ATEZO,
Indications_and_Usage_AVAST, Indications_and_Usage_BRIGA, Indications_and_Usage_CAPMA,
Indications and Usage CEMIP, Indications and Usage CYRAM, Indications and Usage DOXOR,
Indications_and_Usage_DURVA, Indications_and_Usage_ENHER, Indications_and_Usage_ENTRE,
Indications_and_Usage_ERLOT, Indications_and_Usage_ETOP, Indications_and_Usage_ETOPO,
Indications_and_Usage_EXKIV, Indications_and_Usage_GAVRE, Indications_and_Usage_GEFIT,
Indications and Usage GEMZA, Indications and Usage GILOT, Indications and Usage HYCAM,
Indications_and_Usage_IMFIN, Indications_and_Usage_IMJUD, Indications_and_Usage_INFUG,
Indications_and_Usage_IRESS, Indications_and_Usage_KEYTR, Indications_and_Usage_KRAZA,
Indications_and_Usage_LIBTA, Indications_and_Usage_LORBR, Indications_and_Usage_LUMAK,
Indications_and_Usage_LURB, Indications_and_Usage_MEKIN, Indications_and_Usage_METH,
Indications and Usage MVASI, Indications and Usage OPDIV, Indications and Usage PORTR,
Indications_and_Usage_RAMUC, Indications_and_Usage_RETEV, Indications_and_Usage_ROZLY,
Indications and Usage RYBRE, Indications and Usage SELPE, Indications and Usage SOTOR,
Indications and Usage TABRE, Indications and Usage TAFIN, Indications and Usage TAGRIS,
Indications and Usage TAXOT, Indications and Usage TECEN, Indications and Usage TEPME,
Indications_and_Usage_TOPO, Indications_and_Usage_TRAME, Indications_and_Usage_TREME,
Indications and Usage TREXA, Indications and Usage VINOR, Indications and Usage VIZIM,
Indications and Usage XALKO, Indications and Usage YERVO, Indications and Usage ZIRAB,
Indications_and_Usage_ZYKAD, Limited_Stage_SCLC, Living_with_LC_LC, Location_LC, Lurbinectedin_,
Marijuna_Smoking_LC, Medications_LC, Methotrexate_Sodium_, Never-Smokers_LC, Non-
Small Cell LC NSCLC, Non-Small Cell Lung Cancer, Non-Small Cell Medication LC , Non-Smokers LC, Non-
Smokers_NSCLC, Non-Smokers_SCLC, Nutrition_LC, Occupational_Exposure,
Physical_Activity_For_Mitigation_of__LC, Physical_Activity_For_Prevention_Of_LC, Preventative_habits_LC,
Quitting/Not_Smoking_LC, Racial/Ethnic, Radiation_Exposure_LC, Ramucirumab_, Recurring_LC_NSCLC,
Recurring_LC_SCLC, Rural_LC, Second-hand_Smoke_LC, Secondhand_Smoke_LC, Selpercatinib_,
Sensor_Factors_LC, Size_of_the_community_LC, Sleep_LC, Small_Cell_LC, Small_Cell_LC_SCLC,
Small_Cell_Lung_Cancer, Small_Cell_Medication_LC_, Smoke_LC, Smokers_LC, Smokers_NSCLC,
Smokers_SCLC, Smoking_LC, Smoking_Marijuana_LC, Smoking_Other_Drugs_LC, Smoking_Tobacco_LC,
Socioeconomics_LC, Sotorasib_, Stage_0_NSCLC, Stage_1_NSCLC, Stage_1_SCLC, Stage_2_NSCLC,
Stage_3A_NSCLC, Stage_3B_NSCLC, Stage_4_NSCLC, Support_Groups_LC, Symptoms_and_Tests_LC,
Symptoms_NSC, Symptoms_SC, Tests_NSC, Tests_SC, Tobacco_Smoking, Tobacco_Smoking_LC,
Topotecan_Hydrochloride_, Tramentinib_Dimethyl_Sulfoxide, Treatment_Regimens_LC, Tremelimumab-actl_,
```

7/10/23, 11:57 AM Ontology Browser

Urban\_LC, Use\_in\_Specific\_Populations\_ABRAX, Use\_in\_Specific\_Populations\_ADAGR, Use in Specific Populations AFATI, Use in Specific Populations AFINI, Use in Specific Populations AFINIT, Use in Specific Populations ALECE, Use in Specific Populations ALIMT, Use in Specific Populations ALUNB, Use in Specific Populations ALYMS, Use in Specific Populations AMIVA, Use in Specific Populations ATEZO, Use in Specific Populations AVAST, Use in Specific Populations BRIGA, Use in Specific Populations CAPMA, Use\_in\_Specific\_Populations\_CEMIP, Use\_in\_Specific\_Populations\_CYRAM, Use\_in\_Specific\_Populations\_DOXOR, Use\_in\_Specific\_Populations\_DURVA, Use\_in\_Specific\_Populations\_ENHER, Use\_in\_Specific\_Populations\_ENTRE, Use\_in\_Specific\_Populations\_ERLOT, Use in Specific Populations ETOP, Use in Specific Populations ETOPO, Use in Specific Populations EXKIV, Use in Specific Populations GAVRE, Use in Specific Populations GEFIT, Use in Specific Populations GEMZA, Use\_in\_Specific\_Populations\_GILOT, Use\_in\_Specific\_Populations\_HYCAM, Use\_in\_Specific\_Populations\_IMFIN, Use\_in\_Specific\_Populations\_IMJUD, Use\_in\_Specific\_Populations\_INFUG, Use\_in\_Specific\_Populations\_IRESS, Use\_in\_Specific\_Populations\_KEYTR, Use\_in\_Specific\_Populations\_KRAZA, Use\_in\_Specific\_Populations\_LIBTA, Use\_in\_Specific\_Populations\_LORBR, Use\_in\_Specific\_Populations\_LUMAK, Use\_in\_Specific\_Populations\_LURB, Use\_in\_Specific\_Populations\_MEKIN, Use\_in\_Specific\_Populations\_METH, Use\_in\_Specific\_Populations\_MVASI, Use\_in\_Specific\_Populations\_OPDIV, Use\_in\_Specific\_Populations\_PORTR, Use\_in\_Specific\_Populations\_RAMUC, Use in Specific Populations RETEV, Use in Specific Populations ROZLY, Use in Specific Populations RYBRE, Use\_in\_Specific\_Populations\_SELPE, Use\_in\_Specific\_Populations\_SOTOR, Use\_in\_Specific\_Populations\_TABRE, Use\_in\_Specific\_Populations\_TAFIN, Use\_in\_Specific\_Populations\_TAGRIS, Use\_in\_Specific\_Populations\_TAXOT, Use\_in\_Specific\_Populations\_TECEN, Use\_in\_Specific\_Populations\_TEPME, Use\_in\_Specific\_Populations\_TOPO, Use\_in\_Specific\_Populations\_TRAME, Use\_in\_Specific\_Populations\_TREME, Use\_in\_Specific\_Populations\_TREXA, Use\_in\_Specific\_Populations\_VINOR, Use\_in\_Specific\_Populations\_VIZIM, Use\_in\_Specific\_Populations\_XALKO, Use\_in\_Specific\_Populations\_YERVO, Use\_in\_Specific\_Populations\_ZIRAB, Use\_in\_Specific\_Populations\_ZYKAD, Vinorelbine\_Tartrate\_, Warnings\_and\_Precautions\_ABRAX, Warnings\_and\_Precautions\_ADAGR, Warnings and Precautions AFATI, Warnings and Precautions AFINI, Warnings and Precautions AFINIT, Warnings\_and\_Precautions\_ALECE, Warnings\_and\_Precautions\_ALIMT, Warnings\_and\_Precautions\_ALUNB, Warnings\_and\_Precautions\_ALYMS, Warnings\_and\_Precautions\_AMIVA, Warnings\_and\_Precautions\_ATEZO, Warnings and Precautions AVAST, Warnings and Precautions BRIGA, Warnings and Precautions CAPMA, Warnings and Precautions CEMIP, Warnings and Precautions CYRAM, Warnings and Precautions DOXOR, Warnings\_and\_Precautions\_DURVA, Warnings\_and\_Precautions\_ENHER, Warnings\_and\_Precautions\_ENTRE, Warnings\_and\_Precautions\_ERLOT, Warnings\_and\_Precautions\_ETOP, Warnings\_and\_Precautions\_ETOPO, Warnings and Precautions EXKIV, Warnings and Precautions GAVRE, Warnings and Precautions GEFIT, Warnings and Precautions GEMZA, Warnings and Precautions GILOT, Warnings and Precautions HYCAM, Warnings and Precautions IMFIN, Warnings and Precautions IMJUD, Warnings and Precautions INFUG, Warnings and Precautions IRESS, Warnings and Precautions KEYTR, Warnings and Precautions KRAZA, Warnings and Precautions LIBTA, Warnings and Precautions LORBR, Warnings and Precautions LUMAK, Warnings\_and\_Precautions\_LURB, Warnings\_and\_Precautions\_MEKIN, Warnings\_and\_Precautions\_METH, Warnings\_and\_Precautions\_MVASI, Warnings\_and\_Precautions\_OPDIV, Warnings\_and\_Precautions\_PORTR, Warnings and Precautions RAMUC, Warnings and Precautions RETEV, Warnings and Precautions ROZLY, Warnings and Precautions RYBRE, Warnings and Precautions SELPE, Warnings and Precautions SOTOR, Warnings\_and\_Precautions\_TABRE, Warnings\_and\_Precautions\_TAFIN, Warnings\_and\_Precautions\_TAGRIS, Warnings\_and\_Precautions\_TAXOT, Warnings\_and\_Precautions\_TECEN, Warnings\_and\_Precautions\_TEPME, Warnings\_and\_Precautions\_TOPO, Warnings\_and\_Precautions\_TRAME, Warnings\_and\_Precautions\_TREME, Warnings and Precautions TREXA, Warnings and Precautions VINOR, Warnings and Precautions VIZIM, Warnings and Precautions XALKO, Warnings and Precautions YERVO, Warnings and Precautions ZIRAB, Warnings and Precautions ZYKAD

OWL HTML inside